Cellectis (CLLS) Curent Deferred Tax Liability (2024)

Cellectis (CLLS) recorded quarterly Curent Deferred Tax Liability of $122000.0 in Q2 2024, down 10.95% quarter-over-quarter from $137000.0 in Q1 2024.

Cellectis (CLLS) Curent Deferred Tax Liability (2024) Analysis & Trends

Cellectis' Curent Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $122000.0 for Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Curent Deferred Tax (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Cellectis 17.40 Bn 17.21 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2024 122,000.00
Jun 30, 2024 122,000.00
Mar 31, 2024 137,000.00
Mar 31, 2024 137,000.00